Stephen Mitchener's most recent trade in Karyopharm Therapeutics Inc was a trade of 60,000 Common Stock done . Disclosure was reported to the exchange on Feb. 28, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 60,000 | 134,670 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.03 per share. | 28 Feb 2023 | 6,357 | 128,313 (0%) | 0% | 3.0 | 19,257 | Common Stock |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 20,000 | 70,546 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 59,400 | 59,400 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 47,250 | 50,546 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 9.29 per share. | 02 Jun 2021 | 528 | 2,472 (0%) | 0% | 9.3 | 4,905 | Common Stock |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2021 | 1,500 | 1,500 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Stephen Mitchener | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2021 | 1,500 | 3,000 (0%) | 0% | - | Common Stock |